Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SSTR4 | P31391 | 1/20 | 0.34 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.32 |
| ▸ | BACE1 | P56817 | 2/20 | 0.32 |
| ▸ | BACE2 | Q9Y5Z0 | 2/20 | 0.32 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.32 |
| ▸ | GABRA1 | P14867 | 2/20 | 0.32 |
| ▸ | GABRG2 | P18507 | 2/20 | 0.32 |
| ▸ | GABRB3 | P28472 | 2/20 | 0.32 |
| ▸ | GABRA5 | P31644 | 2/20 | 0.32 |
| ▸ | GABRA3 | P34903 | 2/20 | 0.32 |
| ▸ | GABRA2 | P47869 | 2/20 | 0.32 |
| ▸ | GABRA4 | P48169 | 1/20 | 0.32 |
| ▸ | GABRA6 | Q16445 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31728824 | 0.78 | SSTR4 (0.31) | SSTR4BACE1BACE2USP30GABRA1 | |
| SCHEMBL29100813 | 0.77 | SSTR4 (0.44) | SSTR4PDPK1BACE1BACE2 | |
| SCHEMBL31453253 | 0.74 | PDPK1 (0.34) | SSTR4PDPK1BACE1BACE2USP30 | |
| SCHEMBL31453148 | 0.73 | SSTR4 (0.41) | SSTR4PDPK1BACE1USP30 | |
| SCHEMBL31453138 | 0.73 | SSTR4 (0.34) | SSTR4PDPK1USP30 | |
| SCHEMBL17362697 | 0.72 | PDPK1 (0.39) | SSTR4PDPK1USP30 | |
| SCHEMBL26984974 | 0.72 | SSTR4 (0.43) | SSTR4PDPK1BACE1BACE2USP30 | |
| SCHEMBL24196393 | 0.71 | SSTR4 (0.34) | SSTR4PDPK1BACE1BACE2USP30 | |
| SCHEMBL18013606 | 0.71 | SSTR4 (0.42) | SSTR4PDPK1BACE1BACE2USP30 | |
| SCHEMBL25385687 | 0.71 | SYK (0.34) | SSTR4PDPK1BACE1BACE2USP30 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2531498-B1 | COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS | NOVARTIS AG (CH) | 2016-07-13 | — | — | EP | disclosed |
| EP-2531498-B1 | COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS | NOVARTIS AG (CH) | 2016-07-13 | — | — | EP | disclosed |
| US-9181238-B2 | N-(pyridin-2-yl)sulfonamides and compositions thereof as protein kinase inhibitors | NOVARTIS AG (CH) | 2015-11-10 | — | — | US | disclosed |
| US-9181238-B2 | N-(pyridin-2-yl)sulfonamides and compositions thereof as protein kinase inhibitors | NOVARTIS AG (CH) | 2015-11-10 | — | — | US | disclosed |
| US-9181238-B2 | N-(pyridin-2-yl)sulfonamides and compositions thereof as protein kinase inhibitors | NOVARTIS AG (CH) | 2015-11-10 | — | — | US | disclosed |
| US-20130143899-A1 | COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS | NOVARTIS AG | 2013-06-06 | — | — | US | disclosed |
| US-20130143899-A1 | COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS | NOVARTIS AG | 2013-06-06 | — | — | US | disclosed |
| US-20130143899-A1 | COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS | NOVARTIS AG | 2013-06-06 | — | — | US | disclosed |
| EP-2531498-A1 | COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS | IRM LLC (BM) | 2012-12-12 | — | — | EP | disclosed |
| WO-2011097526-A1 | COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS | IRM LLC (BM) | 2011-08-11 | — | — | WO | disclosed |
| WO-2011097526-A1 | COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS | IRM LLC (BM) | 2011-08-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130143899-A1 | COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS | RAF1, BRAF, ARAF | SSTR4 4658/4885PDPK1 160/4885BACE1 3200/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.